Premium
Serum markers of pulmonary epithelial damage in systemic sclerosis‐associated interstitial lung disease and disease progression
Author(s) -
Stock Carmel J.W.,
Hoyles Rachel K.,
Daccord Cecile,
Kokosi Maria,
Visca Dina,
De Lauretis Angelo,
Alfieri Veronica,
Kouranos Vasilis,
Margaritopoulos George,
George Peter M.,
Molyneaux Philip L.,
Chua Felix,
Maher Toby M.,
Abraham David J.,
Ong Voon,
Donovan Jackie,
Sestini Piersante,
Denton Christopher P.,
Wells Athol U.,
Renzoni Elisabetta A.
Publication year - 2021
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13988
Subject(s) - medicine , interstitial lung disease , disease , biomarker , lung , pathology , systemic disease , immunology , biochemistry , chemistry
The clinical course of systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) is highly variable and easily measurable biomarkers are needed to predict disease progression. Serum epithelial biomarker KL‐6 is predictive of disease progression measured by a decline in DL CO , regardless of ILD severity, and could provide increased prognostic ability to inform risk stratification in SSc‐ILD. See related Editorial